A Phase 2/3 Study in Adult and Adolescent Participants With SCD

NCT05431088

Status	RECRUITING
Phase	Phase 2, Phase 3
Sponsor	Pfizer
Enrollment	389 participants

Key Eligibility Criteria

Inclusion (9)

- Part A, Part B, and OLE:
- Male or female with SCD
- Participants with stable Hb value as judged by the Investigator
- For participants taking hydroxyurea and/or L-glutamine, the dose must be stable for at least 90 days prior to signing the ICF or assent and with no anticipated need for dose adjustments during the study in the opinion of the Investigator.
- Part B:

... and 4 more (see full listing online)

Exclusion (5)

- Part A, Part B, and OLE:
- Participants who had more than 10 VOC within 12 months of screening
- Female participant who is breastfeeding or pregnant
- Participants who receive RBC transfusion therapy regularly or received an RBC transfusion ---for any reason within 90 days of Day 1
- Participants hospitalized for sickle cell crisis or other vaso-occlusive event within 14 days of signing the ICF or anytime during the screening period.

Locations (49 total)

Smilow Cancer Hospital, New Haven, Connecticut, United States
Edward Jenner Research Group Center LLC, Plantation, Florida, United States
Pediatric Hematology / Oncology a division of Kidz Medical services, West Palm Beach, Florida, United States
... and 46 more locations